Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.

Journal of cellular and molecular medicine - 1 Nov 2021

Kang Junnan, Zhang Yizhuo, Ding Sa, Yasheng Kalbinur, Li Yueyang, Yu Yong, Wang Yafei, Tian Chen

Abstract excerpt

Triple-hit lymphoma (THL), which is classified into high-grade B-cell lymphoma with rearrangements of MYC, BCL2 and BCL6, presents aggressive biological behaviour. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is considered to be one of the recommended treatment options. Here, we reported 3 THL patients received carmustine, etoposide, cytarabine and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma

Share to Positron Emission Tomography Computed Tomography

Share to Rituximab

Share to Tomography, X-Ray Computed

Share to Transplantation, Autologous

Share to Transplantation Conditioning

Source

Open in PubMed Open full text

Identifiers

PMID: 34698437
DOI: 10.1111/jcmm.16999
PMCID: PMC8581337

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.PMID 34698437Read ↗

Drug therapy for double-hit lymphomaSemantic proximity Read ↗

Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.Semantic proximity Read ↗

Emerging Strategies in Treating Double Hit Lymphomas.Semantic proximity Read ↗

High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/RearrangementsSemantic proximity Read ↗

Ofatumumab as Part of Reduced Intensity Conditioning in High Risk B-cell Lymphoma Patients: Final Long-term Analysis From a Prospective Multicenter Phase-ii TrialSemantic proximity Read ↗

Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.Semantic proximity Read ↗

Progressive Diffuse Large B-cell Lymphoma with TP53 Gene Mutation Treated with Chidamide-Based ChemotherapySemantic proximity Read ↗

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt's lymphoma with TP53 mutations.Semantic proximity Read ↗

MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.Semantic proximity Read ↗

Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma.Semantic proximity Read ↗

Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin LymphomaSemantic proximity Read ↗

Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T Cell Lymphomas; Evidence of Graft-Versus-T Cell Lymphoma EffectSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.